Last reviewed 2026-05-19 · How we verify

Meperon (MOPERONE)

Phase 2 active Small molecule ✓ Verified May 2026

Meperon (generic name: MOPERONE) is a moperone drug. It is currently in Phase 2 development.

Moperone works by blocking the D(3) dopamine receptor, which is involved in regulating the brain's reward and motivation systems.

Meperon is a small molecule with the synonyms MOPERONA, MOPERONE, MOPERONE, MOPERONE HYDROCHLORIDE, and R 1658.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	MOPERONE
Drug class	moperone
Target	D(4) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of dopamine as a chemical messenger that helps us feel pleasure and motivation. When Moperone blocks the D(3) dopamine receptor, it can reduce the brain's response to dopamine, which may help to decrease symptoms of certain psychiatric conditions. This can be helpful for people who experience excessive motivation or pleasure-seeking behaviors.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Meperon CI brief — competitive landscape report
Meperon updates RSS · CI watch RSS

Frequently asked questions about Meperon

What is Meperon?

Meperon (MOPERONE) is a moperone drug.

How does Meperon work?

Moperone works by blocking the D(3) dopamine receptor, which is involved in regulating the brain's reward and motivation systems.

What is the generic name of Meperon?

MOPERONE is the generic (nonproprietary) name of Meperon.

What drug class is Meperon in?

Meperon belongs to the moperone class. See all moperone drugs at /class/moperone.

What development phase is Meperon in?

Meperon is in Phase 2.

What does Meperon target?

Meperon targets D(4) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor and is a moperone.

Drug class: All moperone drugs
Target: All drugs targeting D(4) dopamine receptor, D(2) dopamine receptor, D(3) dopamine receptor
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing